SrasV1, PascalFrancis, Curation, bibRecord, 000443

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

Identifieur interne : 000443 ( PascalFrancis/Curation ); précédent : 000442; suivant : 000444

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

Auteurs : Martin Spruth [Autriche] ; Otfried Kistner [Autriche] ; Helga Savidis-Dacho [Autriche] ; Elisabeth Hitter [Autriche] ; Brian Crowe [Autriche] ; Marijan Gerencer [Autriche] ; Peter Brühl [Autriche] ; Leopold Grillberger [Autriche] ; Manfred Reiter [Autriche] ; Christa Tauer [Autriche] ; Wolfgang Mundt [Autriche] ; P. Noel Barrett [Autriche]

Source :

Vaccine [ 0264-410X ] ; 2006.

RBID : Pascal:06-0108407

Descripteurs français

Pascal (Inist)
- Virus syndrome respiratoire aigu sévère, Vaccin, Immunité humorale, Réponse immune.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Humoral immunity, Immune response, Severe acute respiratory syndrome virus, Vaccine.

Abstract

A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)₃ had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-γ and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 24`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses`
A11	`01`	`1`		`@1 SPRUTH (Martin)`
A11	`02`	`1`		`@1 KISTNER (Otfried)`
A11	`03`	`1`		`@1 SAVIDIS-DACHO (Helga)`
A11	`04`	`1`		`@1 HITTER (Elisabeth)`
A11	`05`	`1`		`@1 CROWE (Brian)`
A11	`06`	`1`		`@1 GERENCER (Marijan)`
A11	`07`	`1`		`@1 BRÜHL (Peter)`
A11	`08`	`1`		`@1 GRILLBERGER (Leopold)`
A11	`09`	`1`		`@1 REITER (Manfred)`
A11	`10`	`1`		`@1 TAUER (Christa)`
A11	`11`	`1`		`@1 MUNDT (Wolfgang)`
A11	`12`	`1`		`@1 BARRETT (P. Noel)`
A14	`01`			`@1 Baxter Vaccines, Biomedical Research Centre, Uferstr. 15 @2 2304 Orth/Donau @3 AUT @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut. @Z 11 aut. @Z 12 aut.`
A20				`@1 652-661`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000135343430140`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 30 ref.`
A47	`01`	`1`		`@0 06-0108407`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)₃ had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-γ and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.
C02	`01`	`X`		`@0 002A05F04`
C03	`01`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Vaccin @5 05`
C03	`02`	`X`	`ENG`	`@0 Vaccine @5 05`
C03	`02`	`X`	`SPA`	`@0 Vacuna @5 05`
C03	`03`	`X`	`FRE`	`@0 Immunité humorale @5 06`
C03	`03`	`X`	`ENG`	`@0 Humoral immunity @5 06`
C03	`03`	`X`	`SPA`	`@0 Inmunidad humoral @5 06`
C03	`04`	`X`	`FRE`	`@0 Réponse immune @5 07`
C03	`04`	`X`	`ENG`	`@0 Immune response @5 07`
C03	`04`	`X`	`SPA`	`@0 Respuesta inmune @5 07`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 065`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000547

Links to Exploration step

Pascal:06-0108407

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses</title>
<author><name sortKey="Spruth, Martin" sort="Spruth, Martin" uniqKey="Spruth M" first="Martin" last="Spruth">Martin Spruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Hitter, Elisabeth" sort="Hitter, Elisabeth" uniqKey="Hitter E" first="Elisabeth" last="Hitter">Elisabeth Hitter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Crowe, Brian" sort="Crowe, Brian" uniqKey="Crowe B" first="Brian" last="Crowe">Brian Crowe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Gerencer, Marijan" sort="Gerencer, Marijan" uniqKey="Gerencer M" first="Marijan" last="Gerencer">Marijan Gerencer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Grillberger, Leopold" sort="Grillberger, Leopold" uniqKey="Grillberger L" first="Leopold" last="Grillberger">Leopold Grillberger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Reiter, Manfred" sort="Reiter, Manfred" uniqKey="Reiter M" first="Manfred" last="Reiter">Manfred Reiter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Tauer, Christa" sort="Tauer, Christa" uniqKey="Tauer C" first="Christa" last="Tauer">Christa Tauer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Mundt, Wolfgang" sort="Mundt, Wolfgang" uniqKey="Mundt W" first="Wolfgang" last="Mundt">Wolfgang Mundt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P. Noel" last="Barrett">P. Noel Barrett</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0108407</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0108407 INIST</idno>
<idno type="RBID">Pascal:06-0108407</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000547</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000443</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses</title>
<author><name sortKey="Spruth, Martin" sort="Spruth, Martin" uniqKey="Spruth M" first="Martin" last="Spruth">Martin Spruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Hitter, Elisabeth" sort="Hitter, Elisabeth" uniqKey="Hitter E" first="Elisabeth" last="Hitter">Elisabeth Hitter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Crowe, Brian" sort="Crowe, Brian" uniqKey="Crowe B" first="Brian" last="Crowe">Brian Crowe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Gerencer, Marijan" sort="Gerencer, Marijan" uniqKey="Gerencer M" first="Marijan" last="Gerencer">Marijan Gerencer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Grillberger, Leopold" sort="Grillberger, Leopold" uniqKey="Grillberger L" first="Leopold" last="Grillberger">Leopold Grillberger</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Reiter, Manfred" sort="Reiter, Manfred" uniqKey="Reiter M" first="Manfred" last="Reiter">Manfred Reiter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Tauer, Christa" sort="Tauer, Christa" uniqKey="Tauer C" first="Christa" last="Tauer">Christa Tauer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Mundt, Wolfgang" sort="Mundt, Wolfgang" uniqKey="Mundt W" first="Wolfgang" last="Mundt">Wolfgang Mundt</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P. Noel" last="Barrett">P. Noel Barrett</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humoral immunity</term>
<term>Immune response</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Vaccin</term>
<term>Immunité humorale</term>
<term>Réponse immune</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)<sub>3</sub>
 had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-γ and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SPRUTH (Martin)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KISTNER (Otfried)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SAVIDIS-DACHO (Helga)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HITTER (Elisabeth)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CROWE (Brian)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GERENCER (Marijan)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BRÜHL (Peter)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GRILLBERGER (Leopold)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>REITER (Manfred)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>TAUER (Christa)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MUNDT (Wolfgang)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>BARRETT (P. Noel)</s1>
</fA11>
<fA14 i1="01"><s1>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15</s1>
<s2>2304 Orth/Donau</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>652-661</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000135343430140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0108407</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)<sub>3</sub>
 had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-γ and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Immunité humorale</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Humoral immunity</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Inmunidad humoral</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Réponse immune</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Immune response</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Respuesta inmune</s0>
<s5>07</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>065</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000443 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000443 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0108407
   |texte=   A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri